Related Experiment Videos
Hormonal changes in patients with haematological malignancies
Biomedicine / [Publiee Pour L'A.A.I.C.I.G.]
|November 1, 1981
Summary
Immunologically reactive insulin (IRI) and growth hormone (GH) levels were elevated in most patients with hematological malignancies. Cytostatic treatment normalized IRI levels, suggesting a link between cancer and these hormones.
Area of Science:
- Endocrinology
- Oncology
- Hematology
Background:
- Hematological malignancies can affect endocrine function.
- Hormonal imbalances may play a role in the progression or manifestation of these diseases.
Purpose of the Study:
- To investigate the levels of key hormones in patients with hematological malignancies.
- To assess the relationship between hormone levels and disease status (relapse vs. remission) and treatment.
Main Methods:
- Sera from patients with various hematological malignancies were analyzed.
- Levels of immunologically reactive insulin (IRI), growth hormone (GH), thyroxine, cortisol, and ACTH were quantified.
Main Results:
- Elevated IRI and GH levels were observed in 80% of patients, irrespective of malignancy type.
- IRI levels were significantly higher during relapse compared to remission.
- Cytostatic therapy effectively normalized elevated IRI serum levels.
- Thyroxine, ACTH, and cortisol levels were elevated in only 2% of patients.
Conclusions:
- Increased IRI and GH are common in hematological malignancies.
- IRI levels correlate with disease activity and respond to cytostatic treatment.
- Endocrine monitoring, particularly for IRI, may be valuable in managing hematological malignancies.